ORPHA:306731
Sydenham chorea
Publications
523
74.8th percentile
Trials
2
Interventional, condition-specific
Researchers
933
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare acquired autoimmune movement disorder characterized by chorea, , and emotional lability. Additional clinical features may include motor impersistence and various neuropsychiatric symptoms. As a major clinical manifestation of acute rheumatic fever (ARF), the disorder typically emerges as a post-infectious complication of a group A streptococcal infection and frequently presents alongside cardiac involvement, such as clinical or subclinical carditis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017648
- UMLS:C0152113
- NCIT:C168445
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
523 matched papers (290 in last 10 years) Source
- Phenotype characterisedPresent
17 HPO annotations (e.g. Dysarthria; Endocarditis; Atypical behavior) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
17
Associated phenotypes · MONDO:0017648
- Dysarthria
- Endocarditis
- Atypical behavior
- Emotional lability
- Inappropriate behavior
Showing 5 of 17 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
523
523 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
523 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
290 in the last 10 years · high confidence · 74.8th percentile (publications denominator)
Phrase hits: 523 · MeSH hits: 0
Who's working on it?
933
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Cunningham MW12 papers · 2024
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. madeleine-cunningham@ouhsc.edu
Papers in Europe PMC - 02Frankovich J11 papers · 2026
Department of Pediatrics, Stanford University of Medicine, Stanford, California, USA.
Papers in Europe PMC - 03Thienemann M8 papers · 2025
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
Papers in Europe PMC - 04Dale RC5 papers · 2025
Neuroinflammation Group, Institute of Neuroscience and Muscle Research, Children's Hospital at Westmead, University of Sydney, Sydney, Australia. Electronic address: russell.dale@health.nsw.gov.au.
Papers in Europe PMC - 05Farhadian B5 papers · 2025
Department of Pediatrics, Stanford University of Medicine, Stanford, California, USA.
Papers in Europe PMC - 06Ma M5 papers · 2025
Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
Papers in Europe PMC - 07Silverman M5 papers · 2025
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
Papers in Europe PMC - 08Swedo SE5 papers · 2025
Section on Behavioral Pediatrics, National Institute of Mental Health (NIMH), Bethesda, MD, United States.
Papers in Europe PMC - 09Cardoso F4 papers · 2025
Movement Disorders Clinic, Neurology Unit, University Hospital, UFMG, Belo Horizonte, Brazil.
Papers in Europe PMC - 10Gao J4 papers · 2026
Department of Pediatrics, Stanford University of Medicine, Stanford, California, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06259006·RECRUITING·TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children
Not reviewed·Conditions: Rheumatic Fever · Sydenham Chorea·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Sydenham chorea — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Sydenham chorea"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Sydenham chorea"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:50:11.219Z